HR7917

The Fair Wages for Home Care Workers Act (HR7917) was introduced on March 12, 2026, by Rep. Ocasio-Cortez and 71 Democratic cosponsors. It has been referred to the House Committee on Education and Workforce. The bill amends the Fair Labor Standards Act to remove the exemption for home care workers (companionship services and live-in domestic service employees) from minimum wage and overtime protections. Currently, these workers are exempt under Section 13(a)(15) and 13(b)(21) of the FLSA. The bill narrows the exemption to only casual babysitting services. There is a companion bill in the Senate (S4081) which has been read twice and referred to committee. The bill does not authorize any funding; it is a regulatory mandate. The money trail is indirect: increased labor costs for home care agencies, which may lead to higher prices for consumers or reduced access to care. No direct government spending is involved. There are no related signals or procurement actions provided in the input, so no convergence analysis is possible. Structural winners and losers: The primary losers are publicly traded home care companies that rely on the current exemption to keep labor costs low. Addus HomeCare (ADUS) and Amedisys (AMED) are the most exposed pure-play home care providers. Larger diversified healthcare companies with home care divisions (e.g., UnitedHealth Group's LHC Group, now part of UNH) would also be affected but to a lesser extent. Non-profit and private home care agencies would face similar cost pressures. There are no clear winners from this bill, as it imposes costs without offsetting benefits for providers. However, home care workers themselves would benefit from higher wages. Timeline: The bill is at the earliest stage (referred to committee). Given the partisan sponsorship and Republican control of the House (assuming the 119th Congress has a Republican majority, though not explicitly stated), the bill has very low probability of advancing. Even if it passed the House, Senate passage would be challenging. The bill is unlikely to become law in this Congress. Investors should monitor for any committee hearings or markups, which would signal increased momentum.